Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...
First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...
Stocktwits on MSN
SLS vs. TERN: Which pharma stock has more upside as Merck eyes $6B cancer bet ahead of Keytruda patent cliff
SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance ...
Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...
FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit ...
Results from the key secondary endpoint of OS showed a 50% reduction in the risk of death for neoadjuvant and adjuvant PADCEV plus KEYTRUDA as compared to surgery alone (HR of 0.50; 95% CI, 0.33-0.74; ...
Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results